HIGHLIGHTS
- who: David A. Angulo et al. from the Inc, Jersey City, NJ, USA Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine have published the paper: Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections, in the Journal: (JOURNAL)
- what: Most of the patients in this study have yeast infections, but data from some patients with mold infections are expected.
SUMMARY
Molds are ubiquitous in the environment and pose a serious and growing threat to public health, especially for patients who are immunocompromised. In . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.